# Trial of TRC105 and Sorafenib in Patients With HCC

> **NCT02560779** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 27 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Carotuximab (TRC105)
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02560779
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560779, "Trial of TRC105 and Sorafenib in Patients With HCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02560779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*